Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Total Liabilities (2020 - 2025)

Ovid Therapeutics' Total Liabilities history spans 6 years, with the latest figure at $20.3 million for Q4 2025.

  • For Q4 2025, Total Liabilities fell 15.32% year-over-year to $20.3 million; the TTM value through Dec 2025 reached $20.3 million, down 15.32%, while the annual FY2025 figure was $20.3 million, 15.32% down from the prior year.
  • Total Liabilities reached $20.3 million in Q4 2025 per OVID's latest filing, up from $19.2 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $56.2 million in Q4 2023 to a low of $10.1 million in Q3 2021.
  • Average Total Liabilities over 5 years is $24.7 million, with a median of $23.0 million recorded in 2022.
  • Peak YoY movement for Total Liabilities: tumbled 64.0% in 2021, then soared 144.55% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $14.8 million in 2021, then soared by 55.38% to $23.0 million in 2022, then skyrocketed by 144.55% to $56.2 million in 2023, then plummeted by 57.42% to $23.9 million in 2024, then fell by 15.32% to $20.3 million in 2025.
  • Per Business Quant, the three most recent readings for OVID's Total Liabilities are $20.3 million (Q4 2025), $19.2 million (Q3 2025), and $21.6 million (Q2 2025).